


Rational Drug Therapy Program


WVBMS Drug Utilization Board February 24, 2016 Presented by Stephen A. Small, M.S., R.Ph. West Virginia University School of Pharmacy



November 2015 Program Summary


EO/PA Status	EO Count	% EO Total	PA Count	% PA Total	Total Count	% of Total
APPROVED	2056	75.48%	2233	57.36%	4289	64.82%
CALLTRACK	0	0.00%	269	6.91%	269	4.07%
CLOSED	62	2.28%	127	3.26%	189	2.86%
DENIED	429	15.75%	932	23.94%	1361	20.57%
INPROCESS	0	3.89%	47	1.21%	47	0.71%
MEDREVIEW	106	2.61%	245	6.29%	351	5.30%
PENDING	71	2.61%	40	1.03%	111	1.68%
Total Program	2724	38.77%	3893	55.41%	6617	94.18%
# Member ID# s	2017	1.35	3201	1.22	6002	1.10






December 2015 Program Summary


EO/PA Status	EO Count	% EO Total	PA Count	% PA Total	Total Count	% of Total
APPROVED	2278	71.14%	2503	57.69%	4781	63.40%
CALLTRACK	0	0.00%	306	7.05%	306	4.06%
CLOSED	53	1.66%	130	3.00%	183	2.43%
DENIED	613	19.14%	1041	23.99%	1654	21.93%
INPROCESS	1	4.56%	55	1.27%	56	0.74%
MEDREVIEW	146	3.47%	256	5.90%	402	5.33%
PENDING	111	3.47%	48	1.11%	159	2.11%
Total Program	3202	40.15%	4339	54.40%	7541	94.55%
# Member ID# s	2381	1.34	3529	1.23	5910	1.28






November 2015 Edit Overrides (EO)

			7026 Disp >		7230	7071
	7069	7073 Early	Exceeds	217	Claim Amount	Ingredient
EO Status	Ther.Dup	Refill	Max	Incarcerated	Threshold	Dup
APPROVED	79.14%	81.87%	62.30%	95.41%	93.75%	89.87%
CLOSED	1.96%	2.76%	3.17%	0.92%	3.75%	1.27%
DENIED	13.01%	11.98%	26.59%	2.75%	2.50%	3.80%
INPROCESS	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
MEDREVIEW	2.50%	2.00%	4.37%	0.00%	0.00%	3.80%
PENDING	3.39%	1.38%	3.57%	0.92%	0.00%	1.27%
Total EO's	1122	651	252	102	80	79






December 2015 Edit Overrides (EO)

					7071	7155 Max RX
Edit Override	7069	7073 Early	7026 Disp >	217	Ingredient	Days Supply
Status	Ther.Dup	Refill	Exceeds Max	Incarcerated	Dup	Limit
APPROVED	74.01%	79.07%	66.01%	89.66%	82.11%	75.00%
CLOSED	1.20%	3.14%	1.31%	4.31%	1.05%	0.00%
DENIED	17.58%	14.50%	25.49%	0.86%	10.53%	10.00%
INPROCESS	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
MEDREVIEW	2.97%	1.64%	4.25%	1.72%	3.16%	5.00%
PENDING	4.24%	1.64%	2.94%	3.45%	3.16%	10.00%
Total EO's	1416	669	306	116	95	80

7069


Ther.Dup



November 2015 PA Stats


	Atypical Anti- psychotics	Narcotic Withdrawal Agents	Anti- convulsants	Amphet- amines	ADD Agents	Direct Factor XA Inhibitors
APPROVED	70.55%	80.20%	66.18%	70.46%	63.16%	79.12%
CALLTRACK	1.82%	12.29%	2.94%	8.86%	3.95%	4.40%
CLOSED	4.73%	1.71%	2.94%	2.53%	3.29%	5.49%
DENIED	15.45%	4.44%	23.90%	13.08%	17.11%	6.59%
INPROCESS	1.09%	0.34%	0.37%	0.00%	0.00%	1.10%
MEDREVIEW	5.27%	0.68%	2.94%	5.06%	10.53%	2.20%
PENDING	1.09%	0.34%	0.74%	0.00%	1.97%	1.10%
Totals	550	293	272	237	152	91

November 2015 PA Status Graph



 OPENDING
 OMEDREVIEW
 OINPROCESS
 ODENIED
 OCLOSED
 OAPPROVED

November 2015 PA Distribution




293

December 2015 PA Stats


	Atypical Anti- psychotics	Narcotic Withdrawal Agents	Anti- convulsants	Amphet- amines	Proton Pump Inhibitors
APPROVED	70.32%	80.53%	69.12%	65.49%	56.00%
CALLTRACK	2.32%	10.56%	6.32%	8.63%	4.00%
CLOSED	5.26%	1.98%	3.16%	2.35%	3.43%
DENIED	14.06%	3.96%	15.44%	14.51%	25.14%
INPROCESS	1.39%	0.33%	0.00%	0.00%	0.57%
MEDREVIEW	4.48%	1.65%	4.91%	9.02%	10.86%
PENDING	2.16%	0.99%	1.05%	0.00%	0.00%
Totals	647	303	285	255	175

		DPP-4	Alpha-2A Rec.	
	ADD Agents	Inhibitors	Agonist	Narcotics
APPROVED	63.35%	56.64%	71.70%	50.55%
CALLTRACK	4.35%	5.31%	0.94%	6.59%
CLOSED	1.86%	2.65%	0.94%	3.30%
DENIED	18.63%	31.86%	20.75%	35.16%
INPROCESS	0.62%	0.88%	0.00%	0.00%
MEDREVIEW	10.56%	1.77%	3.77%	3.30%
PENDING	0.62%	0.88%	1.89%	1.10%
Totals	161	113	106	91

December 2015 PA Status Graph



December 2015 PA Distribution



Therapy Duplications by Class

HIC3	Definition	Count
	November	
H3A	ANALGESICS, NARCOTICS	273
H2S	SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	158
H7C	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	104
A4B	HYPOTENSIVES, SYMPATHOLYTIC	60
H7T	ANTIPSYCHOTICS, ATYPICAL, DOPAMINE, & SEROTONIN ANTAG	59
S2B	NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE	46
D4J	PROTON-PUMP INHIBITORS	39
A4D	HYPOTENSIVES, ACE INHIBITORS	36
C4G	INSULINS	31
H4B	ANTICONVULSANTS	29
	December	
H3A	ANALGESICS, NARCOTICS	262
H2S	SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	149
H2V	TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NARCOLEPSY	118
H7C	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	108
J5B	ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	97
H4B	ANTICONVULSANTS	74
H7T	ANTIPSYCHOTICS, ATYPICAL, DOPAMINE, & SEROTONIN ANTAG	62
D4J	PROTON-PUMP INHIBITORS	55
H2E	SEDATIVE-HYPNOTICS,NON-BARBITURATE	50
S2B	NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE	48

Therapeutic Duplication by Drug

GCN Seqno	Drug Name	Drug Strength	Count					
	November							
057893	DULOXETINE HCL	60 MG	26					
046214	FLUOXETINE HCL	20 MG	26					
057892	DULOXETINE HCL	30 MG	24					
047430	HYDROCODONE/APAP	5 MG-325MG	23					
030623	HYDROCODONE/APAP	10MG-325MG	21					
004222	OXYCODONE HCL/APAP	5 MG-325MG	21					
000347	CLONIDINE HCL	0.2 MG	20					
046405	VENLAFAXINE HCL	150 MG	19					
047431	HYDROCODONE/APAP	7.5-325MG	19					
048977	OXYCODONE HCL/APAP	10MG-325MG	18					
	Decemb	ber						
004561	CLONAZEPAM	1 MG	31					
047430	HYDROCODONE/APAP	5 MG-325MG	29					
046404	VENLAFAXINE HCL	75 MG	26					
048977	OXYCODONE HCL/APAP	10MG-325MG	26					
046214	FLUOXETINE HCL	20 MG	23					
019188	ZOLPIDEM TARTRATE	10 MG	22					
004222	OXYCODONE HCL/APAP	5 MG-325MG	21					
046229	SERTRALINE HCL	100 MG	20					
057893	DULOXETINE HCL	60 MG	20					
057892	DULOXETINE HCL	30 MG	19					

Other Programs

Children Stimulant Program

- Review performed by Child Psychiatrist
- Initial issue turn around response
 - Standardized the initial response
 - Established more definitive Pharmacist review guidelines
 - Standardized an initial approval period to allow time for review
- Documentation from providers was slow at first but as the program has progressed the information is more readily available

Diabetes Medication Program

- Program is seeing more readily available and current A1C's
- Therapy is being reviewed and adjusted
- More questions will arise when the 6 month A1C requirement will be implemented
- Questions have arisen during the reviews about increasing A1C's and unresponsive A1C's.

Sedative/Hypnotic Program

- Matches other state programs
- Implementation not as noisy as anticipated
- Suspected increase in utilization of trazadone
- WVBMS has added flexibility to the reviews for easier reviews.

CDC BOOST Grant - FYI

- Medication Therapy Management for opioid utilizers (OMTM)
- 3 year interventional grant in conjunction with Injury Prevention Center.
- Program Specifics
 - Data are downloaded to a MTM database
 - Cases are reviewed in order of severity (all disease
 - Pharmacy technician contacts patient and reviews medication history
 - MTM Pain Pharmacist reviews case with patient and sends summation letter to patient and prescriber



Any Questions?